Business
Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
- Initial data from ongoing Phase 2a study in geographic atrophy demonstrated ability of GEM103 to durably regulate complement and showed a differentiated
About this update from Disc Medicine, Inc.
[{"type":"text","content":"\n- Initial data from ongoing Phase 2a study in geographic atrophy demonstrated ability of GEM103 to durably regulate complement and showed a differentiated safety profile with no increased risk of CNV \n\n- Completed enrollment in Phase 2a study of GEM103 in wet AMD with six-month data to be shared by year-end\n\n- A randomized, sham-controlled clinical trial to evaluate GEM103’s ability to limit geographic atrophy is planned to initiate in 1H 2022 \n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nGemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today reported its financial results for the second quarter ended June 30, 2021 and provided a business update.\n\n“The initial results shared in June from the ongoing Phase 2a ReGAtta study in patients with geographic atrophy showed biomarker results that support the biological activity of GEM103 and its ability to regulate complement in a dose-dependent and durable manner as early as after just three months of GEM103 administration,” said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics, Inc. “These compelling results, in an open-label, single arm study designed primarily to demonstrate the safety and tolerability of GEM103, met its key endpoint and provides us the confidence to advance to a sham-controlled study designed to assess the efficacy of GEM103 as a potential treatment for geographic atrophy.”\n\nRecent Business and Clinical Highlights\n\n\nAnnounced initial data from ongoing Phase 2a study of GEM103 in patients with geographic atrophy (GA) secondary to dry AMD. In June 2021, Gemini shared initial data from its ongoing ReGAtta study, an open-label Phase 2a trial of its lead product candidate, GEM103, in patients with GA secondary to dry AMD. The single-arm, multiple-dose escalation study design is the first repeat dose experience with GEM103. Initial study data highlighted GEM103’s generally favorable safety and tolerability profile, the primary goal of the study, while also providing evidence of the candidate’s biological activity in patients with dry AMD, achieving another key study goal. Key initial findings include the following:\n\n\nResults indicated GEM103’s ability to regulate complement in a dose-dependent and durable manner by...